Geovax expands rights under nih covid-19 license to include mpox and smallpox

Atlanta, ga, dec. 19, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed patent and biological materials license agreement (the “license agreement”) with the national institute of allergy and infectious diseases (niaid), part of the national institutes of health (nih), in support of geovax's development of a vaccine against sars-cov-2 (covid-19). the amendment expands geovax's commercial license to include mpox and smallpox as additional indications.
GOVX Ratings Summary
GOVX Quant Ranking